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ABSTRACT- Purpose: Toll-like receptor 4 (TLR4) is over-expressed in breast tumors and thus contributing to 
the tumor progression and metastasis. Natural products have drawn attention in cancer immunotherapy due to 
their various biological activities. Curcumin is well investigated in different types of cancer. However, the 
mechanisms underlying its anti-inflammatory actions have not been extensively elucidated.  For this purpose, we 
explored the inhibitory effects of curcumin on lipopolysaccharide (LPS)-induced TLR4 dependent TRIF signaling 
pathway in two subtypes of breast cancer cell lines (MCF-7 and MDA-MB-231) in this study. Methods: In this 
context, the cytotoxicity of curcumin and LPS alone and the combination of curcumin with LPS on these cells 
was evaluated by WST-1 assay.  The expression level of TLR4 and the release of type I interferon (IFN) levels 
were determined after treatment with curcumin and/or LPS by RT-PCR and ELISA analysis, respectively. 
Furthermore, the subcellular localization of TLR4 and interferon regulatory factor 3 (IRF3) were detected by 
immunofluorescence analysis. Results: Curcumin treatment suppressed breast cancer cells viabilities and the 
activation of TLR4-mediated TRIF signaling pathway by the downregulation of TLR4 and IRF3 expression levels 
and the inhibition of type I IFN (IFN-α/β) levels induced by LPS. However, curcumin was more efficient in MDA-
MB-231 cells than MCF-7 cells owing to its greater inhibitory efficacy in the LPS- enhanced TLR4 signaling 
pathway. Furthermore, IFN-α/β levels induced by TLR4 and IRF3 were decreased in these cells following 
curcumin treatment. Conclusions: Consequently, these results demonstrated that the activation of LPS stimulated 
TLR4/TRIF/IRF3 signaling pathway was mediated by curcumin in breast cancer cells, in vitro. However, more 
studies are necessary to examine the curcumin’s anti-inflammatory activities on TLR4/MyD88/NF-κB as well as 





Toll-like receptors (TLRs) play a crucial role in 
immune response by recognizing pathogen-
associated molecular patterns (PAMPs) associated 
with cancer and/or other diseases through different 
intracellular signaling pathway (1-3). TLRs display 
different effects in tumor progression and treatment 
according to the activation of TLRs or TLR 
associated signaling cascades (4). In tumor 
progression, TLRs are overexpressed in different 
types of cancers including lung, prostate and breast 
and promote survival of cancer cells (5-9).  Toll-like 
receptors 4 (TLR4) is one of the most important 
member of the TLR family and is stimulated by 
lipopolysaccharide (LPS) (10). TLR4, which is 
highly expressed in breast cancer cells, exhibits a 
tumor-promoting role, and promotes resistance to 
apoptosis and metastasis. For example, TLR4 and 
myeloid differentiation primary response gene 88 
(MyD88) expression levels in MCF-7 breast cancer 
cells are increased by LPS stimulation while the 
knockdown of TLR4 signaling inhibits the survival 
of breast cancer cells (11,12).  
The activation of TLR4 signaling by LPS 
promotes two different pathways including MyD88 
dependent and MyD88 independent TIR domain 
containing adapter inducing IFN-β (TRIF) pathways. 
MyD88 dependent pathway is regulated by TIRAP 
(TIR domain-containing adaptor protein), 
Interleukin-1 receptor-associated kinases 2 and 4 
(IRAK2 and IRAK4), TNF receptor associated 
factor 6 (TRAF6) and release of NF-κB and induces 
release of different proinflammatory cytokines 
including IL-1β, TNF-α and IL-6.  However, the 
activation of MyD88 independent TRIF pathway is 
based on the internalization of TLR4/TRIF  
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endosomal complex in contrast to MyD88- 
dependent pathway. This pathway is mediated by 
TRIF-related adaptor molecule (TRAM), 
phosphorylation of interferon regulatory factor 3 
(IRF3) and initiation of interferon β (IFN-β) 
transcription (13-16).  
Curcumin is isolated from Curcuma longa L. 
rhizomes and many studies have shown that 
curcumin exerts the anti-inflammatory, anti-viral, 
anti-carcinogenic, anti-proliferative and anti-oxidant 
properties. In the literature, curcumin can potentially 
inhibit the proliferation of cancer cells and enhance 
chemotherapeutic drugs sensitivity by inducing 
apoptosis (17-20). Curcumin can suppress the 
inflammation via the down-regulation of the 
extracellular TLRs activation and the inflammatory 
genes and/or transcription factors (21,22). There has 
been a number of studies indicating the suppressive 
effect of different natural products (shinbaro3, 
curcumin, tanshinones, phloretin, xanthohumol, 
celastrol, garlic compounds etc.) on the different 
TLRs signaling (14, 23-26). Additionally, several 
promising natural compounds (shinbaro3, curcumin, 
tanshinones) exert anti- inflammatory activities by 
suppressing TLR4/MyD88/NF-κB pathway. 
However, there has been no study that investigated 
the potential effects of curcumin on the activation of 
TLR4/TRIF/IRF3 signaling pathway in breast 
cancer, to our knowledge. For this purpose, we 
explored the anti-inflammatory effects of curcumin 
on LPS stimulated TLR4/TRIF/IRF3 signaling 





Culture conditions for cells proliferation   
MCF-7 and MDA-MB-231 cells were used in this 
study. These cells were incubated in Dulbecco’s 
modified Eagle’s medium (DMEM, Thermo Fisher 
Scientific, USA) with 10% heat-inactivated fetal 
bovine serum (FBS) (Gibco, Thermo Fisher 
Scientific, USA) and 1% penicillin/streptomycin 
(Gibco, Thermo Fisher Scientific, USA). All cell 
lines were cultured in a humidified 37 °C incubator 
(Thermo Fisher Scientific, USA) with 5% CO2. All 
cells were counted using Countes II Cell Counter 






Equal number (2x104 cells/well) of these cells were 
cultured in 96-well culture plates, then treated alone 
with different curcumin concentrations (5-100 µM) 
and LPS (2 µM) and the combination of curcumin (5, 
10 and 25 µM) plus LPS (2 µM) for 24 and 48 h. LPS 
was used to stimulate TLR4 signaling pathway. 
Following incubation, the cells were then incubated 
by 10 µL of WST-1 reagent (Biovision, San 
Francisco, CA, USA) at 37°C for 30 minutes in the 
dark conditions. After incubation, the cells were 
examined at 450 nm with 96-well plate reader 
(Allsheng, China). Each experiment was performed 
three replicates. 
 
Real-Time PCR analysis    
Real-time polymerase chain reaction (RT-PCR) 
analysis was performed to analyze the mRNA levels 
of TLR4 in breast cancer cells treated with curcumin 
alone (5, 10 and 25 µM), LPS alone (2 µM) and the 
combination of curcumin plus LPS. Total RNA was 
isolated by using E.Z.N.A.® Total RNA Kit (Omega 
Bio-Tek, Norcross, GA). The purity and 
concentration of isolated RNAs were determined by 
Qubit 4 Fluorometer (Thermo Fisher Scientific, 
Waltham, MA, USA). cDNA was then synthesized 
by using High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific, 
Waltham, MA, USA). RT-PCR was performed by 
TaqMan™ Gene Expression Assay for 
determination of mRNA levels of TLR4 in The 
StepOnePlus™ Real-Time PCR (Applied 
Biosystems, Foster City, CA). β-actin was utilized as 
the endogenous reference gene. Each experiment 
was performed in three replicates. 
 
Immunofluorescence analysis 
Equal number (5x105 cells/well) of breast cancer 
cells were cultured on slides and after 24 hours, the 
cells incubated with LPS (2 µM), curcumin (5, 10 
and 25 µM) and the combination of curcumin plus 
LPS for 48 hours. Then, the cancer cells were fixed 
with 4% cold-paraformaldehyde for 15 minute and 
were incubated in 5% goat serum and 1% Triton X-
100 in 1× PBS for 1 h at room temperature. Then, the 
cells were treated with primary antibody of TLR4 
(1:2000, Santa Cruz Biotechnology, CA, USA) and 
IFN regulatory factor 3 (IRF3) (1:2000, Santa Cruz 
Biotechnology, CA, USA) for 4 hours and incubated 
with secondary antibody (1:1000, Bio-Rad, 
Hercules, California, USA) for 1 h at room 
temperature. Afterwards, the nucleus of cells was 





stained with DAPI. Fluorescent images were 
photographed and examined with an EVOS FL Cell 
Imaging System (Thermo Fisher Scientific, USA). 
 
ELISA analysis 
Conditioned medium was collected from breast 
cancer cells incubated alone with different 
concentrations of curcumin (5, 10 and 25 µM) and 
LPS (2 µM) and the combination of curcumin plus 
LPS for 48 hours. Concentrations of interferon-α 
(IFN-α) and interferon-β (IFN-β) were analyzed by 
ELISA kits (Elabscience, USA). Each experiment 
was conducted in three replicates. Obtained data 
were shown as mean pg of cytokine ±S.D. 
normalized per 100 cells.   
 
Acridine orange (AO) and ethidium bromide 
(EtBr) staining  
Equal number (5x105 cells/well) of cells were 
cultured in 6-well culture plates and treated alone 
with LPS (2 µM), curcumin (5, 10 and 25 µM) and 
the combination of curcumin plus LPS. Then, all 
cells were fixed with 4% cold-paraformaldehyde for 
15 minute and the cells were stained by adding 500 
µL of AO/EtBr for 30 minute in the dark. The cells 
were examined with EVOS FL Cell Imaging System 
(Thermo Fisher Scientific, USA). 
 
STATISTICAL ANALYSIS  
 
All data was statistically evaluated by SPSS 22.0 
(SPSS Inc., Chicago, IL, USA). Data were expressed 
as a mean ± SD of the three experiments. The 
Analysis of Variance (ANOVA) test by Post-Tukey 
test was conducted for multiple comparisons. p<0.05 
was considered to be statistically significant. 
Furthermore,https://dataanalysis.qiagen.com/pcr/arr





Assessment of cell viability 
In order to evaluate curcumin’s anti-proliferative 
effects on breast cancer cells, WST-1 assay was 
performed (Figure 1).  Both breast cancer cells 
proliferation was significantly inhibited by curcumin 
(p<0.01).  However, the inhibitory effects of 
curcumin on MDA-MB-231 cells were greater than 
MCF-7 cells. The IC50 concentration of curcumin 
25.60 ± 2.83 µM and 8.05 ± 0.70 µM in MCF-7 and 
MDA-MB-231 cells, respectively for 48 h (Figure 
1A). The maximum inhibitions were identified at 
doses ≥25 µmol/l for 48 h with similar viability 
percentages. Thus, 5, 10 and 25 µM curcumin were 
selected as suitable doses for further experiments to 
compare curcumin efficacy in MCF-7 and MDA-
MB-231 cells.  Then, we investigated the anti-
inflammatory effects of curcumin on LPS-stimulated 
TLR4 activation in these cells (Figure 1B). We 
determined that curcumin remarkably inhibited the 
viability of breast cancer cells by blocking LPS 
activity (p<0.01). Thus, curcumin exhibited potential 
anti-inflammatory activity in breast cancer cell lines. 
 
The TLR4 expression levels in breast cancer cells 
To investigate the effects of curcumin and LPS alone 
and the combination of curcumin plus LPS on the 
mRNA expression level of TLR4 in breast cancer 
cells, RT-PCR analysis was performed (Figure 2).  In 
principle, MDA-MB-231 cells (13.4- fold) expressed 
a higher level of TLR4 compared with MCF-7 cells 
(nearly 10.1- fold) due to aggressive phenotype after 
LPS stimulation. On the other hand, 25 µM curcumin 
decreased the expression of TLR4 by 1.20- and 0.54-
fold in MCF-7 and MDA-MB-231 cells, respectively 
(p<0.01). Furthermore, LPS stimulation and 25 µM 
curcumin treatment resulted in a significant 4.68- 
and 1.43- fold increase in TLR4 expression in these 
cells, respectively (p<0.01). Therefore, our results 
demonstrated that curcumin treatment suppressed 
LPS-stimulated TLR4 activation in breast cancer 
cells. 
 
The subcellular localization of TLR4 and IRF3 in 
breast cancer cells 
To explore whether curcumin suppresses the 
activation of IRF3, the subcellular localizations of 
TLR4 and IRF3 were observed by 
immunofluorescence staining (Figure 3). We 
observed the cytoplasmic TLR4 and the nuclear 
IRF3 proteins following exposure to LPS in breast 
cancer cells. Furthermore, curcumin decreased the 
activation of TLR4 and IRF3 because we observed 
inactive IRF3, which localized in the cytoplasm. 
However, the cytoplasmic localization of TLR4 and 
the nuclear localization of IRF3 were detected after 
treatment with the combination of curcumin with 
LPS. These results were consistent with gene 
expression analysis. Our findings suggested that 
curcumin reduced the endosomal localization of 
TLR4 and inhibited the nuclear translocation of IRF3 
and thus, curcumin could suppress TLR4/TRIF/IRF3 
signaling pathway.






Figure 1. (A) Cytotoxicity of curcumin (5-100 µM) in MCF7 and MDA-MB-231 cells. (B) Curcumin inhibited LPS (2 µM) 
stimulated inflammation in both breast cancer cells (p<0.05*, p<0.01**).  
 
 
The type I IFN level in breast cancer cells 
To further confirm the suppression of IRF3 activity 
by curcumin, the changes in the level of type I IFN 
were detected in both breast cancer cells (Figure 4). 
Treatment of breast cancer cells with LPS alone 
significantly stimulated the release of IFN-α and 
IFN-β levels (p<0.01).  However, the levels of IFN-
α and IFN-β considerably decreased following 
treatment with curcumin or the combination of 
curcumin with LPS (p<0.01). Furthermore, curcumin 
reduced IFN-α and IFN-β levels to a greater extent 
than curcumin plus LPS combination (p<0.01). As a 
result, curcumin and curcumin plus LPS stimulation 
resulted in a decrease in the level of IFN-α and IFN-
β, and thus curcumin suppressed TLR4/TRIF/IRF3 
signaling pathway. 
 
Observation of morphological changes in breast 
cancer cells 
In order to observe morphological changes in breast 
cancer cell, we used AO/EtBr staining (Figure 5). 
The more rounded cells, plasma membrane blebbing, 





cellular shrinkage, nuclear condensation and 
fragmentation were observed in both breast cancer 
cells following incubation with curcumin alone and 
the combination of curcumin plus LPS. At a 
concentration of 25 µM curcumin, multiple 
segregated apoptotic bodies were especially noticed 
in MDA-MB-231 cells. However, LPS stimulation 
did not alter overall morphology of MCF-7 and 
MDA-MB-231 cells. Thus, our findings indicated 
that curcumin suppressed LPS activity in breast 
cancer cells by inducing apoptotic cell death.  
 
 
Figure 2. The expression level of TLR4 in (A) MCF-7 and (B) MDA-MB-231 cells after treatment with curcumin and LPS 





Curcumin interacts with multiple molecular targets 
through a wide range of biological properties (27-
29). In the current study, the anti-inflammatory 
effects of curcumin on MyD88 independent-TRIF 
signaling pathway were investigated in breast cancer 
cell lines, for the first time. Our findings 
demonstrated that curcumin could potentially 
suppress LPS-stimulated TLR4/TRIF/IRF3 
signaling pathway through the downregulation of 
TLR4 and IRF3 activity and the inhibition of type I 
IFN (IFN-α/β) levels in breast cancer cells. 
Curcumin treatment significantly inhibits the 
proliferation of different subtypes (MCF7, MDA-
MB-231 and BT-474 etc.) of breast cancer cells by 
inducing apoptosis through multiple signaling 
pathways (30-34). Additionally, the molecular 
mechanisms underlying curcumin-mediated 
apoptotic cell death have been identified in the 
literature (35-38). In the current study, curcumin 
showed higher toxicity in MDA-MB-231 cells than 
MCF-7 cells. Moreover, we observed typical 
apoptotic morphological in these cells treating with 
curcumin. However, only a limited number of 
studies have been demonstrated for the anti-
inflammatory effects of curcumin on cancer cells. 
For this purpose, we evaluated the potential effect of 
curcumin on TLR4 signaling and especially 
TLR4/TRIF/IRF3 signaling pathway.  
TLR4 is mainly expressed in innate immune 
cells. TLR4 dimerization is crucial for the activation 
of both the MyD88-dependent and independent 
TRIF signaling pathways and thus, TLR4 plays an 
important role in innate immune response.  The 
TLR4/MyD88 independent signaling pathway is 
mediated by the activation of TRIF, IRF3 and the 
expression of type I IFNs (IFN-α/β) (39-43). 
Previous studies have shown that TLR4 and MyD88 
are over-expressed in breast cancer (11,12,44,45). 
Some natural compounds (luteolin, epigallocatechin-
3-gallate, catechin, 6-shogaol) exhibit anti-
inflammatory effects and mediate 
TLR4/MyD88/NF-κB and/or TLR4/TRIF/IRF3 





signaling pathways (46-48). Furthermore, several 
studies have evaluted the anti-inflammatory effects 
of curcumin on cancer cells (49-51). For instance, 
Huang et al (2013) state that curcumin significantly 
inhibits LPS-induced epithelial mesenchymal 
transition (EMT) in breast cancer cells (MCF-7 and 
MDA-MB-231 cells) through the downregulation of 
NF-κB-Snail activity (49). 
Furthermore, curcumin binds non-covalently to 
myeloid differentiation protein 2 (MD-2), which is 
responsible for LPS recognition and thus, inhibits 
TLR4 mediated signaling pathways in HEK293 cells 
(50,51). Some recent studies have demonstrated that 
curcumin reduces TLR4 expression induced by LPS 
through the TLR4/MyD88/NF-κB signaling 
pathway in traumatic brain injury and also 
atherosclerosis (52, 53). In the present study, our 
findings suggest that curcumin could potentially 
inhibit the activation of LPS-stimulated 




Figure 3 Continued… 
 







Figure 3. The subcellular localization of (A) TLR4 and (B) IRF3 in MCF-7 and MDA-MB-231 cells was observed by 
immunofluorescence staining following incubation with (a) Control, (b) LPS, (c) 5 µM curcumin, (d) 5 µM curcumin + LPS, 
(e) 10 µM curcumin, (f) 10 µM curcumin + LPS, (g) 25 µM curcumin and (h) 25 µM curcumin + LPS, respectively. (Green: 
TLR4 or IRF3 expression, blue: nuclei). 
 
 
Stimulation of TLR4 by LPS increased the viability 
of MCF-7 and MDA-MB-231 cells as well as the 
induction of IRF3 translocation and IFN-α and IFN-
β levels. However, curcumin alone and the 
combination of curcumin with LPS remarkably 
reduced the activation of TLR4/TRIF/IRF3 pathway 
through the downregulation of TLR4 and IRF3 in 
breast cancer cells. Additionally, our findings 
demonstrated that IFN-α and IFN-β levels reduced 
after exposure to curcumin in LPS stimulated breast 
cancer cells. Nevertheless, MDA-MB-231 cells were 
more susceptible to curcumin anti-inflammatory 
activity than MCF-7 cells.






Figure 4. The secreted IFN-α and IFN-β levels were detected in (A) MCF-7 and (B) MDA-MB-231 cells in response to 
curcumin and LPS alone and curcumin and LPS combination (p<0.05*, p<0.01**).  
 
Figure 5. Curcumin and LPS alone and curcumin and LPS-induced apoptotic cell death in the MCF-7 and MDA-MB-231 
cells observed by AO/EtBr staining. [(a) Control, (b) LPS, (c) 5 µM curcumin, (d) 5 µM curcumin + LPS, (e) 10 µM curcumin, 
(f) 10 µM curcumin + LPS, (g) 25 µM curcumin and (h) 25 µM curcumin + LPS, respectively].  





However, the potential effects of curcumin on the 
TLR4/MyD88/NF-κB signaling pathway as well as 
the activation of different TLRs and downstream 
signaling pathways should be further elucidated.  
In conclusion, we evaluated that curcumin 
exerted TLR4 antagonist activity in two different 
subtypes of breast cancer cells through its anti-
inflammatory effects and could mediate 
TLR4/TRIF/IRF3 signaling pathway and IFN 
responses by suppressing of LPS stimulated 
inflammation. However, further molecular studies 
are needed to explore the relationship between 
curcumin anti-inflammatory action and LPS induced 
TLR4/TRIF/IRF3 and TLR4/MyD88/NF-κB 
signaling pathways in breast cancer, in detail. 
Additionally, the link between curcumin and other 
signaling pathways via TLRs activation requires 
further investigation, in vitro.  
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